Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.560
-0.170 (-6.23%)
At close: Jun 1, 2026, 4:00 PM EDT
2.700
+0.139 (5.45%)
After-hours: Jun 1, 2026, 5:49 PM EDT
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Ovid Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.33, which forecasts a 108.20% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $7.00.
Price Target: $5.33 (+108.20%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ovid Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $4 | Buy | Reiterates | $4 | +56.25% | May 26, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $5 | Buy | Maintains | $5 | +95.31% | May 16, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $7 | Buy | Reiterates | $7 | +173.44% | May 14, 2026 |
Unknown Analyst B. Riley Securities No rating | B. Riley Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +95.31% | May 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $7 | Buy | Maintains | $7 | +173.44% | May 13, 2026 |
Financial Forecast
Revenue This Year
175.66K
from 7.25M
Decreased by -97.58%
Revenue Next Year
244.80K
from 175.66K
Increased by 39.36%
EPS This Year
-0.45
from -0.23
EPS Next Year
-0.47
from -0.45
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 892,500 | 1.2M | ||||||
| Avg | 175,664 | 244,800 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -87.7% | 563.8% | ||||||
| Avg | -97.6% | 39.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.36 | -0.36 | |||
| Avg | -0.45 | -0.47 | |||
| Low | -0.64 | -0.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by TipRanks. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.